Physician profile
Peter W Johnson
NPI 1154764728
$1,779.74
in general payments reported to CMS, 2019-2025
25 companies · $281 in 2025
The $281 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $261 · 2021: $149 · 2022: $270 · 2023: $228 · 2024: $61.83 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $570.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $569.52 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $283.67 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $140.76 | 2019 | |
| Ge Healthcare | $133.03 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $91.02 | 2022-2023 | |
| Genentech USA, INC. | $67.54 | 2021-2022 | |
| Boston Scientific Corporation | $49.96 | 2019 | |
| Depuy Synthes Sales INC. | $46.81 | 2021 | |
| Acorda Therapeutics, INC | $41.14 | 2019-2022 | |
| Bausch Health US, LLC | $38.44 | 2019-2025 | Aplenzin |
| Grifols USA, LLC | $28.91 | 2021 | |
| Ucb, INC. | $28.31 | 2019 | |
| Assertio Therapeutics, INC. | $27.75 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.00 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $24.67 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.44 | 2022 | |
| Amgen INC. | $23.45 | 2022 | |
| Collegium Pharmaceutical, INC. | $23.28 | 2025 | Jornay Pm |
| Csl Behring | $20.71 | 2021 | |
| Medtronic USA, INC. | $17.16 | 2020 | |
| Avanir Pharmaceuticals, INC. | $15.49 | 2019 | |
| Lilly USA, LLC | $15.27 | 2019 | |
| Biogen, INC. | $14.99 | 2019 | |
| Allergan, INC. | $13.75 | 2020 | |
| Vertical Pharmaceuticals, LLC | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.